Figure 4
From: Human activated protein C variants in a rat model of arterial thrombosis
Effects of WT hAPC and the two mutants of hAPC combined with hPS in the rat model of arterial thrombosis. Experimental group numbers in A and B refer to the following proteins: 1 = hPS, 2 = WT-hAPC + hPS, 3 = QGNSEDY-hAPC + hPS, 4 = QGNSEDY-hAPC:B148 + hPS, 5 = Vehicle. A. Antithrombotic effect, expressed as the percentage of patent vessels. None of the hAPC variants combined with hPS produced any significant antithrombotic effect, although QNSEDY-hAPC:B148+hPS resulted in an increased patency-rate compared to controls with p = 0.14 (n = 10 in all treatment groups, n = 20 in the control group). B. Arteriotomy bleeding (n = 10 in all treatment groups, n = 20 in the control group). All observations are plotted as well as the 25th, 50th (medians) and 75th percentiles (within boxes). There were no statistical significant differences between the groups.